Toft Group Completes Search for Vice President, Global Customer Operations for Luminex Corporation (Nasdaq:LMNX) in Austin, TX

Executive search firm Toft Group has placed W. Ryan Snellings as Vice President of Global Customer Operations for Luminex Corporation (Nasdaq:LMNX) in Austin, TX.

Mr. Snellings was most recently the Vice President of Operations at Fresenius Kabi, a leading global health care company. He has over 15 years’ experience in service operations and logistics and spent several years working in Europe leading the service team that supports Europe, Middle East, and Africa. Earlier in his industry career, Mr. Snellings served with Baxter Healthcare. Mr. Snellings holds an MBA from the Keller Graduate School of Management and a BS in Information Studies from Florida State University.

About Luminex Corporation

Luminex Corporation offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

Toft Group Completes Search for Manager of Medical Affairs for QOL Medical, LLC. in Vero Beach, FL

Executive search firm Toft Group has placed Lauren Remkus, PharmD, as Manager of Medical Affairs for QOL Medical, LLC. in Vero Beach, FL.

Dr. Remkus was previously Senior Medical Science Liaison at Shire Pharmaceuticals. She joined Shire in May 2013 as Manager, Medical Communications, Global Medical Affairs. Dr. Remkus also served as a Fellow at Janssen Research and Development with responsibility for safety evaluations including review of clinical and post – marketing adverse event case reports. She also authored post-marketing safety documents including periodic safety update report (PSUR) and ad hoc reports written to identify potential adverse drug reactions.
Dr. Remkus holds a PharmD from Touro College of Pharmacy in New York.

About QOL Medical

QOL Medical is a patient-centric company founded in 2003 to focus on the acquisition and commercialization of orphan products in underserved markets. QOL Medical ensures an expanded clinical awareness and patient access for improved quality of life in the treatment of rare and orphan diseases. The Company currently markets two FDA-approved products: Sucraid® (sacrosidase) Oral Solution and Ethamolin® (Ethanolamine Oleate) Injection, 5%.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

Toft Group Completes Search for Vice President, Marketing for Exact Sciences Corp. (Nasdaq: EXAS) in Madison, WI

 

Executive search firm Toft Group has placed Kristen Weiler as Vice President of Marketing with Exact Sciences (Nasdaq: EXAS) in Madison, Wisconsin.

Ms. Weiler has held multiple roles in marketing across a broad range of therapeutic franchises. Her most recent position was as Senior Marketing Director of the Rheumatology portfolio at AbbVie, leading the brand performance of HUMIRA. Earlier in her industry career she led commercial development for ABT-874, anti-IL-12/23 antibody for psoriasis and Crohn’s disease and brand marketing for HUMIRA PsA indication in dermatology while also leading commercial development activities for future psoriasis indication. Ms. Weiler is actively involved in the Crohn’s and Colitis Foundation of America (CCFA) through fundraising and encouraging pediatric drug development.

Ms. Weiler holds a BS in Business Administration/Operations Management from the University of Wisconsin.

About Exact Sciences, Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

Toft Group Completes Search for Senior Medical Director for Leap Therapeutics (NASDAQ: LPTX) in Cambridge, MA

Executive search firm Toft Group has placed Girish Naik, MD, MBA as Senior Medical Director with Leap Therapeutics in Cambridge, MA.

Dr. Naik was previously a clinical researcher at Dana-Farber Cancer Institute. Before this appointment, Dr. Naik was Associate Scientific Manager/Medical Lead – Clinical Development at Biocon Research Ltd. where he was a physician-lead for novel biologics in oncology/immunology. Dr. Naik also served as PG Registrar (Pharmacology and Clinical Pharmacology) at Christian Medical College. He got his start in the medical industry as a surgeon at the M S Ramaiah Medical Teaching and Memorial Hospitals.

Dr. Naik holds an MD in Pharmacology from Christian Medical College in Vellore, India; an MBA from Sikkim Manipal University; and a diploma of advanced studies in pharmaceutical medicine from the University of Basel, Switzerland.

About Leap Therapeutics

Leap Therapeutics (NASDAQ:LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric cancer, biliary tract cancer, and gynecologic cancers, with an emerging focus on patients with defined mutations of the Wnt pathway and in combination with immune checkpoint inhibitors. Leap’s second clinical candidate, TRX518, is a novel, humanized GITR agonist monoclonal antibody designed to enhance the immune system’s anti-tumor response that is in two advanced solid tumor studies.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

 

Toft Group Completes Search for Vice President of Global Clinical Sciences for Greenwich Biosciences in Carlsbad, CA

Executive search firm Toft Group has placed Eduardo Dunayevich, MD, Vice-President of Global Clinical Sciences with Greenwich Biosciences in Carlsbad, CA.

Dr. Dunayevich is a board-certified psychiatrist with clinical development expertise within biotechnology and pharmaceutical companies. He recently served as Chief Medical Officer with Annexon Biosciences, with responsibility for clinical development, clinical operations and regulatory affairs across their neuroinflammation and intraocular therapy programs.

Previously, he held the role of Vice President and Global Product Lead, CNS at Takeda Pharmaceuticals. Prior to joining Takeda, Dr. Dunayevich was Executive Director and Global Development Leader, Neuroscience for Amgen. Dr. Dunayevich also spent 5 years with Orexigen Therapeutics as their Chief Medical Officer. Before that, he worked with Eli Lilly as a Medical Advisor in the Clinical Neuroscience Program Phase. Earlier in his industry career, Dr. Dunayevich served as Director of the Clinical Psychobiology Program, Psychobiology Inpatient Unit and Division of Clinical Trials of the Psychotic Disorders Research Program at the University of Cincinnati.
Dr. Dunayevich holds an MD from the University of Buenos Aires Medical School, Argentina.

About GW Pharmaceuticals plc and Greenwich Biosciences

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA approval for EPIDIOLEX (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older, pending DEA rescheduling. The Company has submitted a regulatory application in Europe for the adjunctive treatment of LGS and Dravet syndrome. The company continues to evaluate EPIDIOLEX in additional rare epilepsy conditions and currently has ongoing clinical trials in tuberous sclerosis complex (TSC) and infantile spasms (IS). GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a U.S. Phase 3 trial. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

Toft Group Completes Search for Chief Technology Officer for ImpediMed Ltd. in Carlsbad, CA

Executive search firm Toft Group has placed Mr. Sashi Tripathi as Chief Technology Officer at ImpediMed Ltd. (ASX: IPD), in ImpediMed’s US office in Carlsbad, CA.

Mr. Tripathi is an accomplished healthcare technology leader. As the SVP of Technology & Operations of New Century Health, he oversaw all aspects of IT, project and product management, product development and operations. He joined New Century Health from Springfield Clinic where he was the Chief Information Officer responsible for strategy, development, management and integration of the organization. Previously, Mr. Tripathi was the VP of IT for Facey Medical.

Earlier in his industry career, Mr. Tripathi served as a Product Development Consultant for Agnity Healthcare and as Global IT Director for St. Jude Medical. Mr. Tripathi holds an MS in Industrial Engineering & Operations Research from the Indian Institute of Technology and a BE in Mechanical Engineering from M.M.M. Engineering College.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About ImpediMed, Ltd.

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

Toft Group Completes Search for Vice President, Information Technology for Synthetic Genomics, Inc. (SGI), in La Jolla, CA

Executive search firm Toft Group has placed Timothy E. Cooley as Vice President, Information Technology at Synthetic Genomics, Inc. (SGI), in La Jolla, CA.

Mr. Cooley has many years of experience in leading information technology in life sciences companies. He has previously served as Director of Business Solutions for MPI Research, Executive Vice President of US Operations at Molecular Health, and CIO for NAMSA. He also volunteers as Chief Data Officer for the Human Health Project. Earlier in his industry career Mr. Cooley spent 15 years with Eli Lilly where he held several roles, most recently as their Director of Information Technology, Medical and Health Outcomes.  Mr. Cooley holds a BS in Microbiology from Texas A&M University

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Synthetic Genomics, Inc.

Synthetic Genomics, Inc. (SGI) is a private biotechnology company harnessing the power of living cells — nature’s most efficient machines — to create transformative medicines and bio-based products. With an unmatched understanding of how DNA and RNA instruct the functions of life, we program cells for improved purpose and function. Our R&D competencies focus on our novel self-amplifying RNA replicon platform for infectious disease and oncology vaccines and therapeutics and our algal cell systems for industrial and biotherapeutic discovery and manufacturing. Built on a legacy of scientific firsts, our team of biological engineers are shaping the future bioeconomy.

Toft Group Completes Search for Chief Financial Officer for aTyr Pharma, Inc. (Nasdaq: LIFE) in San Diego, CA

Executive search firm Toft Group has placed Jill Broadfoot as Chief Financial Officer at aTyr Pharma, Inc. in San Diego, CA. aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways.

Prior to joining aTyr Ms. Broadfoot served as Chief Financial Officer of Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc. where she was responsible for establishing operations for the U.S.-based pharmaceutical and bioceuticals entities as well as the establishment of operations, corporate governance, finance and accounting and investor relations functions. Prior to Emerald Health, Ms. Broadfoot served as Vice President, U.S. Corporate Controller at GW Pharmaceuticals plc, and as Chief Financial Officer of Vical Inc. Before joining Vical, Ms. Broadfoot held various positions at DJO Global, Inc., most recently as Vice President of Finance. Ms. Broadfoot also served as an audit manager at Ernst & Young LLP. Ms. Broadfoot holds a B.S. in business administration and accounting from San Diego State University and is a Certified Public Accountant.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About aTyr

aTyr is a clinical-stage biotechnology company engaged in the discovery and clinical development of innovative medicines using its knowledge of tRNA synthetase biology. aTyr is focused on the therapeutic translation of the Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase (HARS) gene family. aTyr’s clinical stage ATYR1923 candidate augments the Resokine pathway and is designed to temper immune engagement in interstitial lung diseases. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 250 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential protein compositions derived from tRNA synthetase genes.

Toft Group Completes Search for Vice President, Biotherapeutics Research & Development for Codexis, Inc. (NASDAQ: CDXS), in Redwood City, CA

Executive search firm Toft Group has placed Hicham Alaoui, Ph.D. as Vice President, Biotherapeutics Research & Development for Codexis, Inc. in Redwood City, CA.

Dr. Alaoui has more than 20 years of experience with drug discovery and development organizations. Most recently Dr. Alaoui served as Senior Vice President, Discovery Biology and co-head of Research at Symic Bio. Prior to Symic Bio, Dr. Alaoui worked at Genentech, ultimately leading a large in vitro pharmacology group dedicated to lead discovery and optimization for both biotherapeutic and small molecule programs. Prior to Genentech, he worked in R&D leadership positions at Stryker Biotech, VisEn Medical, Neogenesis Pharmaceuticals, and Shire BioChem.

Dr. Alaoui earned a Ph.D. in Microbiology and Immunology at McGill University, Montreal, Quebec, and an M.Sc. in Biochemistry from Pierre and Marie Curie Université, Paris.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Codexis, Inc.

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes.

Toft Group Completes Search for Member, Board of Directors for Cell Medica in Houston, TX

Executive search firm Toft Group has placed Julia P. Gregory as Non-Executive Director and Audit Chair of Board of Directors for Cell Medica in Houston, TX.

Ms. Gregory has extensive experience in senior roles in the biopharmaceutical industry as well as more than 20 years of investment banking experience.  She currently serves as a non-executive director of several biopharmaceutical companies, including Sosei Group Corporation and Biohaven Pharmaceuticals.  Ms. Gregory is also Chairman and CEO of the biotechnology financial and management advisory firm Isometry Advisors, Inc.

In her previous executive roles, Ms. Gregory served as Chief Executive Officer, Chief Financial Officer and Board Director of ContraFect Corporation; President and CEO of Five Prime Therapeutics; and Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc.  Her corporate development experience includes leading transactions with GlaxoSmithKline, Human Genome Sciences, Genentech, Bristol-Myers Squibb Company and Takeda Pharmaceutical.

Prior to working in the biopharmaceutical industry, Ms. Gregory was an investment banker. Ms. Gregory has also served on the Board of Directors at The Global TB Alliance for Drug Development, Clinipace Worldwide, and the Institute for the Study of Aging, a private foundation for Alzheimer’s.

Ms. Gregory holds an MBA from the Wharton School at the University of Pennsylvania and a BA from George Washington University.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Cell Medica

Cell Medica is committed to transforming patients’ lives through developing the significant therapeutic potential of cellular immunotherapy for the treatment of cancer. In collaboration with strategic partners, Cell Medica is developing a range of products using three proprietary technology platforms including activated T cells, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs). Cell Medica’s lead product is CMD-003 and is being tested in an international Phase II trial for the treatment of cancers associated with the oncogenic Epstein Barr virus. Cell Medica is working with the Baylor College of Medicine and the University of North Carolina to develop next generation CAR- modified NKT cells including an off-the-shelf product. In the field of engineered TCRs, they are collaborating with University College London to develop the Dominant TCR technology platform.

Cell Medica is headquartered in London with subsidiaries in Zurich and Houston.